SGBCC International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
